Jun 07th 2013 - Edison Investment Research today published a report on Biotie Therapies Corp entitled "An Option In Epilepsy". In summary, the report says:
Biotie’s portfolio review has landed its first target, with a $1m option deal to acquire Neurelis for its intranasal diazepam to treat acute epileptic seizures. We view the $1m cash upfront, $8.75m exercise price (in Biotie shares) and cost of development as relatively modest for a new product opportunity with $100m peak sales for the reference product. Meanwhile, Biotie’s tozadenant is now the leading A2a antagonist in development for Parkinson’s disease, following the failure of Merck & Co’s preladenant in Phase III studies. Both developments are potentially positive for Biotie in the long run, although we maintain our €231m (€0.51 per share) valuation.
Edison Investment Research is a leading international investment research company. It has won industry recognition, with awards both in the UK and internationally. The team of 95 includes over 60 analysts supported by a department of supervisory analysts, editors and assistants. Edison writes on more than 400 companies across every sector and works directly with corporates, fund managers, investment banks, brokers and other advisers. Edison’s research is read by institutional investors, alternative funds and wealth managers in more than 100 countries. Edison, founded in 2003, has offices in London, New York and Sydney and is authorised and regulated by the Financial Services Authority (www.fsa.gov.uk/register/firmBasicDetails.do?sid=181584). more »